Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers: Molecular Rationale, Clinical Evidence, and Translational Barriers
International Journal of Molecular Sciences · 10.08.2026 · 27 (16) · 7155
DOI: 10.3390/ijms27167155 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.08.2026. Verfasst von Ludovica Pepe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy. Hauptthemen laut MEDLINE: Neoplasm, Residual, Endometrial Neoplasms, Uterine Cervical Neoplasms. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Endometrial and cervical cancers can recur from subclinical disease not evident on routine surveillance. This narrative review critically evaluates liquid biopsy for minimal residual disease (MRD) assessment and recurrence monitoring. Post-treatment human papillomavirus (HPV) circulating tumor DNA (ctDNA) in cervical cancer has the strongest disease-specific prospective evidence of clinical validity; persistent detection is strongly associated with recurrence, but moderate sensitivity and false-negative results do not support treatment de-escalation on negativity alone. With regard to endometrial cancer, perioperative ctDNA has prognostic support from an 11-study, 1298-patient meta-analysis and additional cohorts, although assay heterogeneity and limited independent replication constrain clinical readiness. Postoperative positivity generally shows stronger associations than preoperative detection. Cervicovaginal and urine DNA-methylation studies provide preliminary evidence for detecting established recurrence, especially local recurrence, but not prospective molecular lead time or clinical utility. Digital PCR, disease-specific fixed panels, tumor-informed assays, and error-corrected sequencing serve distinct settings; broad pan-cancer plasma profiling remains mainly an advanced-disease tool. Circulating tumor cells, extracellular vesicles, microRNAs, tumor-educated platelets, and fragmentomics remain exploratory. Liquid biopsy should remain an investigational adjunct until prospective trials show that acting on molecular findings improves outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
- PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy.
- Division of Medical Oncology, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
- Section of Legal Medicine, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy.
ORCID-Profile: Valeria Zuccalà, Walter Giuseppe Giordano, Vincenzo Cianci, Massimiliano Berretta, Vincenzo Fiorentino, Antonio Ieni
Zitieren
APA
Pepe, L., Zuccalà, V., Giordano, W. G., Di Mauro, G., Cianci, V., Mondello, C., Berretta, M., Fiorentino, V., & Ieni, A. (2026). Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers: Molecular Rationale, Clinical Evidence, and Translational Barriers. International Journal of Molecular Sciences, 27(16), 7155. https://doi.org/10.3390/ijms27167155
Vancouver
Pepe L, Zuccalà V, Giordano WG, Di Mauro G, Cianci V, Mondello C, et al. Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers: Molecular Rationale, Clinical Evidence, and Translational Barriers. International Journal of Molecular Sciences. 2026;27(16):7155. doi:10.3390/ijms27167155
BibTeX
@article{Pepe2026,
author = {Pepe, Ludovica and Zuccalà, Valeria and Giordano, Walter Giuseppe and Di Mauro, Giordana and Cianci, Vincenzo and Mondello, Cristina and Berretta, Massimiliano and Fiorentino, Vincenzo and Ieni, Antonio},
title = {Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers: Molecular Rationale, Clinical Evidence, and Translational Barriers},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7155},
doi = {10.3390/ijms27167155}
}
EUVIMED